文献速递神经核医学肿瘤 PET/CT

三种新型Tau放射性药物11C-RO-963、11C-RO-643和18F-RO-948在健康对照与阿尔茨海默病受试者中的特征研究

Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects.
PubMed 文献 · J Nucl Med · 2018-05-04

本研究首次在人体中评估三种新型Tau PET示踪剂。动态90分钟扫描显示,18F-RO-948在脑内摄取最高,其SUV比和总分布容积能清晰区分阿尔茨海默病组与健康对照组,且动力学特性优于另外两种示踪剂。

要点

  • 18F-RO-948的SUVpeak最高,其次为11C-RO-963,11C-RO-643最低。
  • 11C-RO-643和18F-RO-948的SUV比及总分布容积可区分AD组与健康对照组。
  • 18F-RO-948在高Tau沉积与低Tau沉积预测区域间对比度更好。

核心结论

  • 18F-RO-948在表征AD中Tau病理方面优于11C-RO-643和11C-RO-963。
  • 18F-RO-948的区域结合数据和动力学特性与其他现有Tau PET示踪剂相比具有优势。

研究设计与样本

  • 淀粉样蛋白PET阳性的阿尔茨海默病受试者和年轻对照者各接受2种不同的Tau示踪剂。
  • 弹丸注射11C-RO-963、11C-RO-643或18F-RO-948后行90分钟动态扫描。
  • 对11名健康对照和11名AD受试者行动脉采血。
  • 5名年长对照各接受2次18F-RO-948扫描以评估重测变异性。
  • 4名AD受试者在首次扫描后6-22个月重复18F-RO-948扫描。

主要发现

  • 在年轻对照中,颞叶SUVpeak约为:11C-RO-963约3.0,11C-RO-643约1.5,18F-RO-948约3.5。
  • 在所有脑区和受试者中,趋势为18F-RO-948的SUVpeak最高,其次为11C-RO-963,再次为11C-RO-643。
  • 11C-RO-643和18F-RO-948的SUV比及总分布容积区域分析清晰区分AD组与健康对照组。
  • 房室模型证实11C-RO-643的脑内进入低于11C-RO-963或18F-RO-948。
  • 18F-RO-948在(预测的)高Tau沉积与低Tau沉积区域间显示出更好的对比度。

关键数值与推荐

  • 在22个高结合区域中,13个显示显著组间差异(方差分析后,F(1,21)=45,P<10^-5)。
  • 体素分析显示AD受试者结合高于健康对照的对称簇(阈值P<0.001,簇大小>50)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

11C-RO-963, 11C-RO-643, and 18F-RO-948 (previously referred to as 11C-RO6924963, 11C-RO6931643, and 18F-RO6958948, respectively) have been reported as promising PET tracers for tau imaging based on in vitro and preclinical PET data. Here we describe the first, to our knowledge, human evaluation of these novel radiotracers. Methods: Amyloid PET-positive Alzheimer disease (AD) subjects and younger controls each received 2 different tau tracers. Dynamic 90-min scans were obtained after bolus injection of 11C-RO-963, 11C-RO-643, or 18F-RO-948. Arterial blood sampling was performed on 11 healthy controls and 11 AD subjects. Regions were defined on MR images, and PET data were quantified by plasma reference graphical analysis (for total distribution volume) and target cerebellum ratio (SUV ratios of 60- to 90-min frames). SUV ratio images were also analyzed voxelwise. Five older controls each underwent 2 scans with 18F-RO-948 for evaluation of test-retest variability. Four AD subjects underwent a repeated 18F-RO-948 scan 6-22 mo after the first scan. Six additional healthy controls (3 men and 3 women; age range, 41-67 y) each underwent 1 whole-body dosimetry scan with 18F-RO-948. Results: In younger controls, SUVpeak was observed in the temporal lobe with values of approximately 3.0 for 11C-RO-963, 1.5 for 11C-RO-643, and 3.5 for 18F-RO-948. Over all brain regions and subjects, the trend was for 18F-RO-948 to have the highest SUVpeak, followed by 11C-RO-963 and then 11C-RO-643. Regional analysis of SUV ratio and total distribution volume for 11C-RO-643 and 18F-RO-948 clearly discriminated the AD group from the healthy control groups. Compartmental modeling confirmed that 11C-RO-643 had lower brain entry than either 11C-RO-963 or 18F-RO-948 and that 18F-RO-948 showed better contrast between (predicted) areas of high versus low tau accumulation. Thus, our subsequent analysis focused on 18F-RO-948. Both voxelwise and region-based analysis of 18F-RO-948 binding in healthy controls versus AD subjects revealed multiple areas where AD subjects significantly differed from healthy controls. Of 22 high-binding regions, 13 showed a significant group difference (after ANOVA, F(1,21) = 45, P < 10-5). Voxelwise analysis also revealed a set of symmetric clusters where AD subjects had higher binding than healthy controls (threshold of P < 0.001, cluster size > 50). Conclusion:18F-RO-948 demonstrates characteristics superior to 11C-RO-643 and 11C-RO-963 for characterization of tau pathology in AD. Regional binding data and kinetic properties of 18F-RO-948 compare favorably with other existing tau PET tracers.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Wong DF, Comley RA, Kuwabara H, et al. Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects. J Nucl Med. 2018. PMID: 29728519. doi:10.2967/jnumed.118.209916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。